Skip to main content
SpringerLink
Log in

Infektiöse Endokarditis – Epidemiologie, Diagnostik und Therapie

  • Published:
Wiener klinische Wochenschrift Education

An Erratum to this article was published on 13 October 2015

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Notes

  1. Health care-associated IE: Auftreten von Symptomen einer IE > 48 Stunden nach Aufnahme in ein Krankenhaus, oder innerhalb der ersten 48 h nach Aufnahme wenn zuvor enger Kontakt mit Gesundheitseinrichtungen wie Dialysezentren, Ambulatorien oder Heimpflege bestand.

  2. Community-acquired IE: Auftreten von Symptomen einer IE < 48 nach Aufnahme in ein Krankenhaus und wenn die Kriterien einer health care-associated IE nicht erfüllt sind.

  3. nicht schmerzhafte, hämorrhagische Läsionen im Bereich der Handflächen/Fußsohlen.

  4. etwa linsengroße, schmerzhafte, rötliche Knötchen im Bereich der Finger und Zehen.

  5. Retinablutungen verursacht durch Immunkomplex-Vaskulitiden.

Literatur

  1. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363(9403):139–49.

    Article  PubMed  Google Scholar 

  2. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169(5):463–73.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Benito N, Miro JM, de Lazzari E, Cabell CH, del Rio A, Altclas J, et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med. 2009;150(9):586–94.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Letaief A, Boughzala E, Kaabia N, Ernez S, Abid F, Ben Chaabane T, et al. Epidemiology of infective endocarditis in Tunisia: a 10-year multicenter retrospective study. Int J Infect Dis. 2007;11(5):430–3.

    Article  PubMed  Google Scholar 

  5. Nkomo VT. Epidemiology and prevention of valvular heart diseases and infective endocarditis in Africa. Heart. 2007;93(12):1510–9.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis. 2000;30(2):3740i.

  7. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009;30(19):2369–413.

    Article  PubMed  Google Scholar 

  8. Mandell GL, Benett JE, Dolin R. Endocarditis and Intravascular Infections. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Natasha Andjelkovic; 2010.

  9. Everett ED, Hirschmann JV. Transient bacteremia and endocarditis prophylaxis. A review. Medicine. 1977;56(1):61–77.

    Article  CAS  PubMed  Google Scholar 

  10. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293(24):3012–21.

    Article  CAS  PubMed  Google Scholar 

  11. Chang FY, MacDonald BB, Peacock JE Jr, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine. 2003;82(5):322–32.

    Article  PubMed  Google Scholar 

  12. Chirouze C, Athan E, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect. 2013;19(12):1140ic.

  13. Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther. 2008;6(5):6378rt.

  14. Orsi GB, Ciorba V. Vancomycin resistant enterococci healthcare associated infections. Ann Ig. 2013;25(6):485–92.

    CAS  PubMed  Google Scholar 

  15. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One. 2013;8(5):e63181.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965from . Clin Infect Dis. 2001;32(1):5001i.

  17. Evangelista A, Gonzalez-Alujas MT. Echocardiography in infective endocarditis. Heart. 2004;90(6):614–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Lamas CC, Eykyn SJ. Blood culture negative endocarditis: analysis of 63 cases presenting over 25 years. Heart. 2003;89(3):258–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):6330i.

  20. Hoen B, Beguinot I, Rabaud C, Jaussaud R, Selton-Suty C, May T, et al. The Duke criteria for diagnosing infective endocarditis are specific: analysis of 100 patients with acute fever or fever of unknown origin. Clin Infect Dis. 1996;23(2):2986ica.

  21. Dodds GA, Sexton DJ, Durack DT, Bashore TM, Corey GR, Kisslo J. Negative predictive value of the Duke criteria for infective endocarditis. Am J Cardiol. 1996;77(5):403–7.

    Article  CAS  PubMed  Google Scholar 

  22. Gilbert DNM RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford Guide To Antimicrobial Therapy 2013. 43rd ed. Sperryville: Antimicrobial Therapy, Inc.; 2013.

  23. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44(2):1907i.

  24. Cosgrove SE, Vigliani GA, Fowler VG, Jr., Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48(6):7139ic.

  25. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):2851ic.

  26. Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013;42(3):202–10.

    Article  CAS  PubMed  Google Scholar 

  27. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394–434.

    Article  PubMed  Google Scholar 

  28. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother. 2004;53(6):1018–32.

    Article  CAS  PubMed  Google Scholar 

  29. European Centre of Disease Prevention and Control. Proportion of Aminopenicillins Resistant (R + I) Enterococcus faecalis Isolates in Participating Countries in 2012. 2012. http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/map_reports.aspx.

  30. Pericas JM, Cervera C, del Rio A, Moreno A, Garcia de la Maria C, Almela M, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect. 2014;20(12):O1075cal.

  31. Lye DC, Hughes A, O'Brien D, Athan E. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis. 2005;24(11):753–5.

    Article  CAS  PubMed  Google Scholar 

  32. Garzoni C, Nobre VA, Garbino J. Candida parapsilosis endocarditis: a comparative review of the literature. Eur J Clin Microbiol Infect Dis. 2007;26(12):915–26.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sektion für Infektiologie und Tropenmedizin, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich

    Jürgen Prattes & Ines Zollner-Schwetz

Authors
  1. Jürgen Prattes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ines Zollner-Schwetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Prattes.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prattes, J., Zollner-Schwetz, I. Infektiöse Endokarditis – Epidemiologie, Diagnostik und Therapie. Wien. Klin. Wochenschr. Educ 10, 45–59 (2015). https://doi.org/10.1007/s11812-015-0071-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11812-015-0071-8

Search

Navigation